Nanoviricides (NNVC.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov15

Nanoviricides released FY2026 Q1 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1044 (forecast USD -0.18)

04:00

Nov14

NanoViricides Raises $6 Million Through Institutional Investor Agreement

22:17

Nov10

NanoViricides’ NV-387 Drug Receives Approval for Phase 2 Clinical Trials in Congo

13:31

Oct27

NanoViricides Inc. to Present NV-387 Progress at PODD 2025 Conference

12:46

Oct20

NanoViricides Inc.'s NV-387 Completes Phase I Trial, Moves to Phase II

12:45

Oct15

NanoViricides Plans NV-387 Clinical Trials Against MPox and Respiratory Viruses

12:47

Schedules & Filings

Schedules

Filings

Nov14

Earning Release(EST)

FY2026 Q1 Earning Release (USD) Net Income -1.785 M, EPS -0.1044

Sep29

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -2.096 M, EPS -0.1295

May15

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -2.217 M, EPS -0.1383

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More